Doheny Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Doheny Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,895	Closed	-$301K	–	103
2021 Q1	$301K	Buy	+2,895	New	+$275K	0.2%	86
2019 Q4	–	Sell	-7,035	Closed	-$295K	–	98
2019 Q3	$295K	Buy	7,035 +4,178	+146%	+$164K	0.26%	81
2019 Q2	$142K	Buy	+2,857	New	+$238K	0.12%	90

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Doheny Asset Management's IMDX Position: Q2 2021 in Review

Doheny Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2021, closing a stake of 2,895 shares — an estimated $301K sold.

Doheny Asset Management first reported a position in IMDX in Q2 2019 and held it in 3 quarters. The position peaked at $301K in Q1 2021. 90 funds tracked by Wall St. Rank hold IMDX as of Q2 2021.

Doheny Asset Management reported no remaining Insight Molecular Diagnostics position as of Q2 2021 after selling out during the quarter.
Doheny Asset Management sold 2,895 Insight Molecular Diagnostics shares in Q2 2021, an estimated $301K.
Doheny Asset Management first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 3 quarters.
Doheny Asset Management's Insight Molecular Diagnostics position peaked at $301K in Q1 2021.
90 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2021.

Based on Doheny Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.